Tisch Cancer Institute
The mission of The Tisch Cancer Institute (TCI), under the leadership of Dr. Steven Burakoff, is to build upon Mount Sinai Health System’s history of medical breakthroughs to offer new hope for those living with or at risk for cancer. The dedicated TCI team of basic science and clinical faculty are investigating the mechanisms behind the differentiation and growth of cancer cells and working to move discoveries quickly into therapeutic treatments. Institute members span across multiple departments in the medical center and work in multidisciplinary research programs such as Cancer Immunology, Cancer Mechanisms, Hepatocellular Carcinoma, Myeloid Malignancies and Cancer Prevention and Control. To facilitate pertinent clinical research, the Tisch Cancer Institute provides oversight of all clinical trials through its Protocol Review and Monitoring Committee and its centralized database of clinical trial protocols and enrollments. As of September 2012, cancer grant awards exceeded $41 million in direct costs, and in 2012, there were 129 open therapeutic clinical trials that enrolled a total of 222 new patients.
As part of its mission, the Tisch Cancer Institute supports several Shared Resources dedicated for cancer researchers. These include three clinical resources: Cancer Clinical Trials Office, Cancer Biostatistics, and Cancer Biorepository (in collaboration with the Department of Pathology), as well as many basic sciences resources: Flow Cytometry, Mouse Genetics, Microscopy, Genomics (in collaboration with the Genomics Institute), Immune Monitoring Core, Integrated Screening and Induced Pluripotent Stem Cell. In addition, the TCI provides competitive Research Awards to both basic and clinical cancer scientists to facilitate new insights into cancer biology and cancer treatment.
For more information:
Last update: March 13, 2013
Tisch Cancer Institute [PDF]